Dutasteride

證據等級: L5

預測適應症: 10 個

Dutasteride: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Dutasteride is a dual 5α-reductase inhibitor (types 1 and 2), widely used off-label and approved internationally for benign prostatic hyperplasia (BPH) and androgenetic alopecia, though it holds no Singapore marketing authorisation. The TxGNN model predicts it may be effective for Ambras Type Hypertrichosis Universalis Congenita with a near-perfect model score (99.99%), yet zero clinical trials and zero publications currently support this specific direction. Across all 10 TxGNN-ranked predictions, the model consistently clusters hair and connective tissue disorders — reflecting Dutasteride's known androgen–hair biology link — but mechanistic relevance varies substantially across specific disease subtypes.

Quick Overview

Item	Content
Original Indication	Benign Prostatic Hyperplasia (BPH); Androgenetic Alopecia (international approvals; no Singapore registration found)
Predicted New Indication	Ambras Type Hypertrichosis Universalis Congenita
TxGNN Prediction Score	99.99%
Evidence Level	L5
Singapore Market Status	✗ Not Marketed (0 registrations)
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current Evidence Pack (Data Gap DG002). Based on established pharmacological knowledge, Dutasteride is a dual inhibitor of 5α-reductase isoenzymes type 1 and type 2, blocking the conversion of testosterone to dihydrotestosterone (DHT). This dual inhibition suppresses serum DHT by approximately 90–95% — a more complete reduction than Finasteride, which targets only type 2. Its clinical utility in conditions driven by androgen-dependent tissue responses (prostate enlargement, follicular miniaturisation in androgenetic alopecia) is well-established globally.

Ambras Syndrome (Ambras type hypertrichosis universalis congenita) is a rare congenital disorder caused by a chromosomal inversion at 8q23.3 affecting the TRPS1 gene, resulting in generalised, non-patterned excessive hair growth across the entire body. Critically, this condition is androgen-independent: the hair overgrowth is driven by a developmental genetic defect, not by elevated DHT or over-active 5α-reductase activity.

The extremely high TxGNN prediction score (99.99%, rank 102) most likely reflects knowledge-graph path connectivity along the route "hair disorder → DHT pathway → 5α-reductase inhibitor" rather than a true disease-specific mechanism. Since Ambras Syndrome does not involve androgen excess or signalling dysregulation, inhibiting 5α-reductase provides no direct therapeutic rationale for this genetically-defined condition. This prediction is assessed as a likely false positive arising from imprecise disease categorisation within the knowledge graph.

Clinical Trial Evidence

Currently no related clinical trials registered for Ambras Type Hypertrichosis Universalis Congenita and Dutasteride.

Literature Evidence

Currently no related literature available for Ambras Type Hypertrichosis Universalis Congenita and Dutasteride.

Singapore Market Information

Dutasteride is currently not registered in Singapore. No marketing authorisations have been identified in the regulatory database. Patients requiring Dutasteride-containing products would need to access them through special import or unregistered drug channels.

Safety Considerations

Please refer to the package insert for safety information.

Note: Safety data (key warnings, contraindications) were not available in this Evidence Pack (Data Gap DG001 — package insert not retrieved). No drug–drug interaction records were identified in the DDI database query. Before any clinical use or trial planning, a full safety review against the international label (e.g., Avodart SmPC/USPI) is mandatory.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite an extremely high TxGNN model score (99.99%), the mechanistic basis for Dutasteride in Ambras Type Hypertrichosis Universalis Congenita is non-existent — the disease is caused by a TRPS1 chromosomal inversion unrelated to androgen signalling, and there is no supporting clinical trial or published literature evidence. This prediction is most likely a knowledge-graph artefact.

To proceed, the following is needed:

Retrieve full safety data from the Dutasteride package insert (TFDA or international SmPC/USPI) to close Data Gap DG001 (Blocking severity)
Retrieve complete MOA data from the DrugBank API to close Data Gap DG002 (High severity)
Conduct a formal Singapore HSA regulatory pathway assessment before any local clinical use
Prioritise re-evaluation of Rank 8 (Diffuse Alopecia Areata / Female Androgenetic Alopecia, Evidence Level L4): the retrieved literature (PMID 41714473, 2026 narrative review of AGA in women) provides indirect mechanistic support for Dutasteride's off-label use in female androgenetic alopecia — a clinically distinct and more mechanistically plausible target; if the disease classification is confirmed as androgenetic rather than autoimmune alopecia areata, the evidence level could be upgraded to L3–L2 and the recommendation revised to Proceed with Guardrails
For Rank 2 (Hypertrichosis, general), clarify whether the target subtype is androgenic (Hirsutism) — if so, a limited mechanistic rationale exists and further literature search is warranted
All remaining ranked predictions (Ranks 1, 3–7, 9–10) involve either genetic structural defects, developmental malformations, or neurological disorders with no plausible androgen-axis connection; these are recommended for permanent Hold unless new biological evidence emerges
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.